- Home
- CZNC vs MNPR Comparison
CZNC vs MNPR Comparison
Compare CZNC & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CZNC
- MNPR
- Stock Information
- Founded
- CZNC 1864
- MNPR 2014
- Country
- CZNC United States
- MNPR United States
- Employees
- CZNC N/A
- MNPR N/A
- Industry
- CZNC Major Banks
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- CZNC Finance
- MNPR Health Care
- Exchange
- CZNC Nasdaq
- MNPR Nasdaq
- Market Cap
- CZNC 286.0M
- MNPR 249.5M
- IPO Year
- CZNC N/A
- MNPR 2019
- Fundamental
- Price
- CZNC $19.10
- MNPR $39.42
- Analyst Decision
- CZNC
- MNPR Strong Buy
- Analyst Count
- CZNC 0
- MNPR 5
- Target Price
- CZNC N/A
- MNPR $59.50
- AVG Volume (30 Days)
- CZNC 35.1K
- MNPR 18.1K
- Earning Date
- CZNC 04-23-2025
- MNPR 05-20-2025
- Dividend Yield
- CZNC 5.86%
- MNPR N/A
- EPS Growth
- CZNC 15.34
- MNPR N/A
- EPS
- CZNC 1.75
- MNPR N/A
- Revenue
- CZNC $108,114,000.00
- MNPR N/A
- Revenue This Year
- CZNC $9.38
- MNPR N/A
- Revenue Next Year
- CZNC $3.77
- MNPR N/A
- P/E Ratio
- CZNC $10.93
- MNPR N/A
- Revenue Growth
- CZNC 5.33
- MNPR N/A
- 52 Week Low
- CZNC $16.50
- MNPR $1.72
- 52 Week High
- CZNC $22.68
- MNPR $54.30
- Technical
- Relative Strength Index (RSI)
- CZNC 47.86
- MNPR 49.46
- Support Level
- CZNC $18.75
- MNPR $37.81
- Resistance Level
- CZNC $19.39
- MNPR $44.40
- Average True Range (ATR)
- CZNC 0.53
- MNPR 3.61
- MACD
- CZNC 0.06
- MNPR -0.38
- Stochastic Oscillator
- CZNC 38.79
- MNPR 18.32
About CZNC Citizens & Northern Corp
Citizens & Northern Corp is a community bank operating through its subsidiaries. It provides banking services, including deposit and loan products for personal and commercial customers. The bank also maintains a trust division that provides a wide range of financial services, such as 401(k) plans, retirement planning, estate planning, estate settlements and asset management.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.